PDCD1 and glioblastoma: In an effort to distinguish those patients with GBM capable of exhibiting durable response to ICB as documented previously (1, 4, 63), we reported two clinical studies designed to identify molecular features associated with response to anti–PD-1 immunotherapy (4, 6).